



### Company Overview

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

### CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer

Dec 10 2018, 4:05 PM EST

### CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

Nov 26 2018, 9:00 AM EST

### CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 14 2018, 4:03 PM EST

### Stock Overview

**Symbol** CWBR  
**Exchange** Nasdaq  
**Market Cap** 158.74m  
**Last Price** \$3.73  
**52-Week** \$2.55 - \$10.789

### Investor Relations

Jon Stern, COO  
Investor Relations  
T: (650) 446-7888  
jon.stern@cohbar.com

01/18/2019 04:00 PM EST

### Management Team

#### Philippe P. Calais, Pharm. D., Ph.D.

Chief Executive Officer

#### Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

#### Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

#### Jon L. Stern, MBA

Chief Operating Officer, Director

### CohBar, Inc.

1455 Adams Drive  
Suite 2050  
Menlo Park, CA 94025

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.